NSPR - Earnings announcements

MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast an

MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in international demand for CGuard.Supported over 500 cumulative carotid procedures utilizing CGuard Prime across leading hospitals and integrated delivery networks since launch.Co

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the star

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

--- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approvalAnnounced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use du

MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting the E

– Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. – – Announced approval of an IDE application to initiate the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures – – Established its Headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in H1 2025, if approved – Achieved another record high revenue and unit quarter of $1.81M and 3,121 respectively in served markets-- Management to host investor conference call today, Novem

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2024 financial results on Tuesday, November 12th, 2024, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Third Quarter 2024 Financial Results and

- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial – - On track to submit a Premarket Approval (PMA) application to the FDA this quarter - - Raised gross proceeds of $17.9 million from full exercise of Series H warrants triggered by announcement of C-GUARDIANS data - --Management to host investor conference call today, August 6th, at 8:30am ET-- TEL AVIV, Israel and MIAMI, Aug. 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention S

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Second Quarter 2024 Financial Results and Corporate Update Conference Ca

- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-31 - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company's CGUARDIANS II clinical trial for Transcarotid Artery Revascularization (TCAR), as well as Dr. William Gray, as advisor to the company - -- Management to host investor conference call today, May 14, at 8:30am ET -- TEL AVIV, Israel and MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Insp

TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD First Quarter 2024 Financial Results andCorporate Update Conference Call and WebcastDate:Tuesday, May 14th, 2024Time:8:30 a.m. ETConfere

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company's C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TCAR), as well as Dr. William Gray, as advisor to the company - --Management to host investor conference call today, March 6, at 8:30am ET-- TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30 am (EST) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Fourth Qu

- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –            - Announced support for CMS' final decision expanding coverage of CAS to include both asymptomatic and standard risk patients, significantly expanding the U.S. CAS addressable market –            - Generated Q3 2023 CGuard EPS revenue of $1.56 million, an increase of nearly 9% over Q3 2022 – --Management to host investor conference call today, November 6th, at 8:30am ET-- TEL AVIV, Israel and

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday, November 6th, 2023, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EST) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Third Quarter 2023 Financial Results and Corporate Update Conferenc

Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to minimally invasive CAS and TCAR procedures InspireMD advancing both CAS and TCAR stent delivery platforms along U.S. and E.U. regulatory pathways leveraging proven CGuard EPS stent system TEL AVIV, Israel and MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced its support for the Centers for Medicare and Medicaid Services (CMS) final National

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 – - Generated Q2 2023 CGuard EPS revenue of $1.6 million, an increase of nearly 10% over Q2 2022 – --Management to host investor conference call today, August 8, at 8:30am ET-- TEL AVIV, Israel, and MIAMI, Aug. 08, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Second Quarter 2023 Financial Results and Corporate Update Confer

           - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company's CE Mark certification until mid-March - - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Anticipates re-certification under new Medical Device Regulation (MRD) framework in coming weeks - - Continued enrollment in the C-Guardian US IDE trial; on track to complete enrollment by end of Q2 2023 - - Management to host investor conference call today, May 16t

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to review first quarter 2023 financial and operating results on Tuesday, May 16th, 2023, before the markets open. Title:InspireMD First Quarter 2023 Financial Results and Corporate Update Conference Call and WebcastDate:Tuesday, May 16th, 2023Time:8:30 a.m. ETConference Call Details:Toll-Free: 1-844-826-3035International: 1-412-317-5195To utilize the

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will now report first quarter 2023 financial results on Monday, May 15th, 2023.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD First Quarter 2023 Financial Results and Corporate Update Conference Call and WebcastDate:Monday, May 15th,

Procedure performed as part of the company's ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system CGuardians enrollment on track to be completed by the end of Q2 2023 TEL AVIV, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first carotid artery disease patient has been treated utilizing CGuard Prime, the company's next generation CAS stent platform. The procedure was performed by Dr. Anish Thomas of Mercy Hospital South in St. Louis, MO, as part of Ins

TEL AVIV, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2023 financial results on Tuesday, May 9th, 2023, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD First Quarter 2023 Financial Results and Corporate Update Conference Call and WebcastDate:Tuesday, May 9th, 2023Time:8:30 a.m. ETConfere

- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 -            - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) framework in coming weeks -            - Continued enrollment in the C-Guardian US IDE trial, with 20 sites currently enrolling patients; on track to complete enrollment by approximately end of Q2 2023 - --Management to host investor conference call today, March 30, at 8:30am ET-- TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2022 financial results on Thursday, March 30, 2023, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments.  Title:InspireMD Fourth Quarter and Full Year 2022 Financial Results and Corpor

- Generated 38.8% growth in CGuard™ revenue year-over-year -            - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 -            - Announced strategic partnership with NAMSA, a med tech contract research organization (CRO), to accelerate new medical device development and commercialization - --Management to Host Investor Conference Call Today, November 8th, at 8:30am ET-- TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery di

TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2022 financial results on Tuesday, November 8th, 2022, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Third Quarter 2022 Financial Results and Corporate Update Conference Call and WebcastDate:Tuesday, November 8th, 2022Time:8:30 a.m. ETCon

- Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company - --Management to Host Investor Conference Call Today, August 9th, at 8:30am ET-- TEL AVIV, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial and operating results for the second quarter ended June 30,

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2022 financial results on Tuesday, August 9th, 2022, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments.  Title:InspireMD Second Quarter 2022 Financial Results and Corporate Update Conference Call

           - 20% growth in CGuard™ revenue Year-over-Year -            - C-Guardian FDA IDE Trial Completes First European Enrollment -            - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages -            - European logistics hub established with BOMI Group –for direct market access as well as establishing the commercial footprint for a growing portfolio of new systems across different channels –            - Upcoming Clinical Evidence and Live Case to be presented at LINNC 2022- --Management to Host Investor Conference Call Today, May 10, at 8:30am ET -- TEL AVIV, Israel, May 10, 2022 (G

TEL AVIV, Israel, April 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens. Management will host a conference call and webcast with the investment community at 8:30 am (ET) that same day to review financial results and provide an update on corporate developments. Title:InspireMD First Quarter 2022 Financial Results and Corporate Update Conference Call and Webcast  Date:Tuesday, May 10, 2022  Time:8:30 a.m. ET  Conference Call Det

- CGuard™ Revenue Generated 87.5% growth over Q4'20 and 55.9% Year-over-Year –- - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Established Reimbursement Approval for CGuard from the French National Authority - - CGuard Included as Carotid Stent Treatment Option in National Institute of Neurological Disorders and Stroke (NINDS) Sponsored CREST-2 Trial Following FDA Approval of IDE Supplement Application - --Management to Host Investor Conference Call Today, March 8, at 8:30am ET-- TEL AVIV, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Emboli

-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- TEL AVIV, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, before the market opens. Management will host a conference call and webcast with the investment community at 8:30 am (ET) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Fourth Quarter and Full Year 2021 Financial

-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France-  - $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first half of 2023- -Management to host Call & Webcast Today, November 9, 2021, at 8:30am ET- TEL AVIV, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the third quart

TEL AVIV, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens. Management will host a conference call and webcast with the investment community at 8:30 am (ET) that same day to review financial results and provide an update on corporate developments. Title:InspireMD Third Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast  Date:Tuesday, November 9, 2021  Time:8:30 a.m. E

Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET TEL AVIV, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the second quarter ended June 30, 2021. Second Quarter 2021 and recent highlights Revenue of $1,038,000, an increase of 231.6% compared to the same period in 2020Initiated U.S. enrollment in the "C-Guardians" IDE clinical trial. Eleven (11) patients treated and enrolled in the fir

TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fiscal first quarter 2021 financial results on Tuesday, August 10, 2021, before the market opens. Management will host a conference call on Tuesday, August 10, at 8:30 a.m. ET to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. Participants are asked to pre-register for the call through the following link: https://dpregister.com/